Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 8, 2009, Pages 769-779

  Sorrentino, Carlo ^a   Di Carlo, Emma ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ss Annunziata Hospital   (Italy)

Author keywords

Cytokines; Inflammation; Lung cancer; Tumor microenvironment

Indexed keywords

CD209 ANTIGEN; CD68 ANTIGEN; CYTOKINE; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PATHOPHYSIOLOGY; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR VASCULARIZATION; UPREGULATION;

AGED; CARCINOMA; FEMALE; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 70349878484     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200903-0400OC     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
3. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
4. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808. (Pubitemid 46294612)
5. Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 2008;15:130-139.
6. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-343. (Pubitemid 47181718)
7. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 2007;7:1405-1421. (Pubitemid 351826907)
8. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008;663:208-217.
9. Prendergast GC. Inflammatory mediators in cancer etiology and targets for therapy and prevention. Cancer Reviews Online.[Accessed 2009 Mar 12]. 2008:17-18. Available from: http://canreviews.aacrjournals.org.
10. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992;148:597-603.
11. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131-142.
12. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005;102:16309-16314. (Pubitemid 41688910)
13. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007;149:480-486. (Pubitemid 47256156)
14. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X, Chan ED, Yoon DY, Ottenhoff T, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-gamma dependent mechanism. PLoS Med 2006;3:e277. (Pubitemid 44338369)
15. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:894-901.
16. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, Dinarello CA. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008;181:557-565.
17. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006;103:3298-3303. (Pubitemid 43346464)
18. Csernok E, Holle JU, Gross WL. Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis. Clin Exp Rheumatol 2008;26(3, Suppl 49)S112-S117.
19. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim JH, Kim EJ, Park DK, Kim SH, et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 2008;18:1606-1612.
20. Ko NY, Chang SH, Lee JH, Kim NW, Kim YM, Choi WS, Choi JD, Bae SY, Hong JW, Jaekal J, et al. Unique expression of a small IL-32 protein in the Jurkat leukemic T cell line. Cytokine 2008;42:121-127.
21. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008;105:2865-2870.
22. Sobin LH, Witteking CH. TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss; 2002.
23. Hong WK, Tsao AS. Lung carcinoma. In: Porter RS, Kaplan JL, Homeier BP, Beers MH, editors. The Merck manual online. Whitehouse Station, NJ: Merck Research Laboratories; 2008. Available from: www.merck.com/mmpe/sec05/ch062/ ch062b.html.
24. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001;54:257-271.
25. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006;1:331-348.
26. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart, 3rd ed. World Health Organization international classification of tumors. Geneva: WHO Press; 2004.
27. Sorrentino C, Scarinci A, D'Antuono T, Piccirilli M, Di Nicola M, Pasquale M, Di Iorio C, Di Carlo E. Endomyocardial infiltration by B and NK cells foreshadows the recurrence of cardiac allograft rejection. J Pathol 2006;209:400-410. (Pubitemid 43997750)
28. Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 2005;205:82-91. (Pubitemid 40029096)
29. Westra WH. Early glandular neoplasia of the lung. Respir Med 2000;1:163-169.
30. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006;1:S13-S19.
31. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
32. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54:12-27.
33. Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E. Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev 2008;17:2180-2187.
34. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008;3:e3077.
35. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009;18:215-222.
36. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300-4309.
37. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer 2005;50:309-317. (Pubitemid 43300631)
38. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007;13:2825-2830. (Pubitemid 46849555)
39. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436. (Pubitemid 44050137)
40. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. NF-κB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun 2008;376:283-287.
41. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, Drakesmith H, Davies K, Kessler B, McMichael A, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007;8:569-577. (Pubitemid 46785120)
42. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009;9:465-479.
43. Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, Gao Y, Kang L, Hao Q, Peng G, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE 2008;3:e1985. (Pubitemid 352003402)
44. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999;188:369-377. (Pubitemid 29327434)
45. Yilmaztepe Oral A, Ulukaya E, Yilmaz Y. VEGF, VEGF-receptors and lung cancer. Advancesin Moecularl Medicine 2007;3:15-21.
46. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006;53:91-96. (Pubitemid 43831360)
47. Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A, del Val Toledo Lobo M. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non small cell lung cancer. Cancer 2009;115:1701-1712.
48. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
49. Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:S7-S16.
50. Wakelee H, Sandler A, Keller S, Gandara D, Valleries E, Graziano S, Battafarano R, Butts C, Adjei AA. Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>4cm)-IIIA non-small lung cancer (NSCLC), [ECOG-E1505]. Eastern Cooperative Oncology Group. (Accessed 2009 Jul 15) Available from: http://www.cancer.gov/clinicaltrials/ECOG-E1505.